1. Home
  2. BBAI vs SNDX Comparison

BBAI vs SNDX Comparison

Compare BBAI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BigBear.ai Inc.

BBAI

BigBear.ai Inc.

HOLD

Current Price

$3.82

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$23.66

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBAI
SNDX
Founded
2020
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BBAI
SNDX
Price
$3.82
$23.66
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$5.50
$84.17
AVG Volume (30 Days)
33.3M
1.2M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$31.26
$112.05
Revenue Next Year
N/A
$51.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
627.84
52 Week Low
$2.36
$8.59
52 Week High
$9.39
$25.16

Technical Indicators

Market Signals
Indicator
BBAI
SNDX
Relative Strength Index (RSI) 39.47 62.04
Support Level $3.66 $19.46
Resistance Level $4.52 $25.16
Average True Range (ATR) 0.25 1.24
MACD 0.04 0.15
Stochastic Oscillator 16.89 74.79

Price Performance

Historical Comparison
BBAI
SNDX

About BBAI BigBear.ai Inc.

BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: